|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
DeSantis CE, Lin CC, Mariotto AB, Siegel
RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer
treatment and survivorship statistics, 2014. CA Cancer J Clin.
64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chow WH, Dong LM and Devesa SS:
Epidemiology and risk factors for kidney cancer. Nat Rev Urol.
7:245–257. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pantuck AJ, Zisman A and Belldegrun AS:
The changing natural history of renal cell carcinoma. J Urol.
166:1611–1623. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
DiBiase SJ, Valicenti RK, Schultz D, Xie
Y, Gomella LG and Corn BW: Palliative irradiation for focally
symptomatic metastatic renal cell carcinoma: Support for dose
escalation based on a biological model. J Urol. 158:746–749. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fabian MR, Sonenberg N and Filipowicz W:
Regulation of mRNA translation and stability by microRNAs. Annu Rev
Biochem. 79:351–379. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guo H, Ingolia NT, Weissman JS and Bartel
DP: Mammalian microRNAs predominantly act to decrease target mRNA
levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
McManus MT: MicroRNAs and cancer. Semin
Cancer Biol. 13:253–258. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Farazi TA, Spitzer JI, Morozov P and
Tuschl T: miRNAs in human cancer. J Pathol. 223:102–115. 2011.
View Article : Google Scholar :
|
|
11
|
Garzon R and Marcucci G: Potential of
microRNAs for cancer diagnostics, prognostication and therapy. Curr
Opin Oncol. 24:655–659. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kong LM, Liao CG, Zhang Y, Xu J, Li Y,
Huang W, Zhang Y, Bian H and Chen ZN: A regulatory loop involving
miR-22, Sp1, and c-Myc modulates CD147 expression in breast cancer
invasion and metastasis. Cancer Res. 74:3764–3778. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guo S, Bai R, Liu W, Zhao A, Zhao Z, Wang
Y, Wang Y, Zhao W and Wang W: miR-22 inhibits osteosarcoma cell
proliferation and migration by targeting HMGB1 and inhibiting
HMGB1-mediated autophagy. Tumour Biol. 35:7025–7034. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang C, Ning S, Li Z, Qin X and Xu W:
miR-22 is down-regulated in esophageal squamous cell carcinoma and
inhibits cell migration and invasion. Cancer Cell Int. 14:1382014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang X, Yu H, Lu X, Zhang P, Wang M and Hu
Y: miR-22 suppresses the proliferation and invasion of gastric
cancer cells by inhibiting CD151. Biochem Biophys Res Commun.
445:175–179. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang G, Xia S, Tian H, Liu Z and Zhou T:
Clinical significance of miR-22 expression in patients with
colorectal cancer. Med Oncol. 29:3108–3112. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Song SJ and Pandolfi PP: miR-22 in
tumorigenesis. Cell Cycle. 13:11–12. 2014. View Article : Google Scholar :
|
|
18
|
He H, Wang L, Zhou W, Zhang Z, Wang L, Xu
S, Wang D, Dong J, Tang C, Tang H, et al: MicroRNA expression
profiling in clear cell renal cell carcinoma: Identification and
functional validation of key miRNAs. PLoS One. 10:e01256722015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vaziri H, Dessain SK, Ng Eaton E, Imai SI,
Frye RA, Pandita TK, Guarente L and Weinberg RA: hSIR2(SIRT1)
functions as an NAD-dependent p53 deacetylase. Cell. 107:149–159.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Langley E, Pearson M, Faretta M, Bauer UM,
Frye RA, Minucci S, Pelicci PG and Kouzarides T: Human SIR2
deacetylates p53 and antagonizes PML/p53-induced cellular
senescence. EMBO J. 21:2383–2396. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li JY, Yong TY, Michael MZ and Gleadle JM:
Review: The role of microRNAs in kidney disease. Nephrology
(Carlton). 15:599–608. 2010. View Article : Google Scholar
|
|
22
|
Xiao H, Zeng J, Li H, Chen K, Yu G, Hu J,
Tang K, Zhou H, Huang Q, Li A, et al: miR-1 downregulation
correlates with poor survival in clear cell renal cell carcinoma
where it interferes with cell cycle regulation and metastasis.
Oncotarget. 6:13201–13215. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Qiu M, Liang Z, Chen L, Tan G, Wang K, Liu
L, Liu J and Chen H: MicroRNA-429 suppresses cell proliferation,
epithelial-mesenchymal transition, and metastasis by direct
targeting of BMI1 and E2F3 in renal cell carcinoma. Urol Oncol.
33:332.e9–e18. 2015. View Article : Google Scholar
|
|
24
|
Li X, Xin S, He Z, Che X, Wang J, Xiao X,
Chen J and Song X: MicroRNA-21 (miR-21) post-transcriptionally
downregulates tumor suppressor PDCD4 and promotes cell
transformation, proliferation, and metastasis in renal cell
carcinoma. Cell Physiol Biochem. 33:1631–1642. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gurha P, Abreu-Goodger C, Wang T, Ramirez
MO, Drumond AL, van Dongen S, Chen Y, Bartonicek N, Enright AJ, Lee
B, et al: Targeted deletion of microRNA-22 promotes stress-induced
cardiac dilation and contractile dysfunction. Circulation.
125:2751–2761. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pasqualini L, Bu H, Puhr M, Narisu N,
Rainer J, Schlick B, Schäfer G, Angelova M, Trajanoski Z, Börno ST,
et al: miR-22 and miR-29a are members of the androgen receptor
cistrome modu lating LAMC1 and Mcl-1 in prostate cancer. Mol
Endocrinol. 29:1037–1054. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xiong J1, Yu D, Wei N, Fu H, Cai T, Huang
Y, Wu C, Zheng X, Du Q, Lin D and Liang Z: An estrogen receptor
alpha suppressor, microRNA-22, is downregulated in estrogen
receptor alpha-positive human breast cancer cell lines and clinical
samples. FEBS J. 277:1684–1694. PubMed/NCBI
|
|
28
|
Poliseno L, Salmena L, Riccardi L, Fornari
A, Song MS, Hobbs RM, Sportoletti P, Varmeh S, Egia A, Fedele G, et
al: Identification of the miR-106b~25 microRNA cluster as a
proto-oncogenic PTEN-targeting intron that cooperates with its host
gene MCM7 in transformation. Sci Signal. 3:ra292010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dong YJ, Liu N, Xiao Z, Sun T, Wu SH, Sun
WX, Xu ZG and Yuan H: Renal protective effect of sirtuin 1. J
Diabetes Res. 2014:8437862014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huffman DM, Grizzle WE, Bamman MM, Kim JS,
Eltoum IA, Elgavish A and Nagy TR: SIRT1 is significantly elevated
in mouse and human prostate cancer. Cancer Res. 67:6612–6618. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jang KY, Kim KS, Hwang SH, Kwon KS, Kim
KR, Park HS, Park BH, Chung MJ, Kang MJ, Lee DG, et al: Expression
and prognostic significance of SIRT1 in ovarian epithelial tumours.
Pathology. 41:366–371. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jung YJ, Lee JE, Lee AS, Kang KP, Lee S,
Park SK, Lee SY, Han MK, Kim DH and Kim W: SIRT1 overexpression
decreases cisplatin-induced acetylation of NF-κB p65 subunit and
cytotoxicity in renal proximal tubule cells. Biochem Biophys Res
Commun. 419:206–210. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Stünkel W, Peh BK, Tan YC, Nayagam VM,
Wang X, Salto-Tellez M, Ni B, Entzeroth M and Wood J: Function of
the SIRT1 protein deacetylase in cancer. Biotechnol J. 2:1360–1368.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen J, Zhang B, Wong N, Lo AW, To KF,
Chan AW, Ng MH, Ho CY, Cheng SH, Lai PB, et al: Sirtuin 1 is
upregulated in a subset of hepatocellular carcinomas where it is
essential for telomere maintenance and tumor cell growth. Cancer
Res. 71:4138–4149. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yamakuchi M, Ferlito M and Lowenstein CJ:
miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci
USA. 105:13421–13426. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xu JQ, Liu P, Si MJ and Ding XY:
MicroRNA-126 inhibits osteosarcoma cells proliferation by targeting
Sirt1. Tumour Biol. 34:3871–3877. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Deng S, Zhu S, Wang B, Li X, Liu Y, Qin Q,
Gong Q, Niu Y, Xiang C, Chen J, et al: Chronic pancreatitis and
pancreatic cancer demonstrate active epithelial-mesenchymal
transition profile, regulated by miR-217-SIRT1 pathway. Cancer
Lett. 355:184–191. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang H, Feng Z, Huang R, Xia Z, Xiang G
and Zhang J: MicroRNA-449 suppresses proliferation of hepatoma cell
lines through blockade lipid metabolic pathway related to SIRT1.
Int J Oncol. 45:2143–2152. 2014.PubMed/NCBI
|
|
39
|
Liu Y, Li X, Zhu S, Zhang JG, Yang M, Qin
Q, Deng SC, Wang B, Tian K, Liu L, et al: Ectopic expression of
miR-494 inhibited the proliferation, invasion and chemoresistance
of pancreatic cancer by regulating SIRT1 and c-Myc. Gene Ther. Apr
28–2015.Epub ahead of print. View Article : Google Scholar
|
